Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.
CalciMedica, Inc. (Nasdaq: CALC) is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. Its news flow is driven by clinical trial progress, preclinical publications, regulatory interactions, financing activities, and scientific presentations related to its lead CRAC channel inhibitor Auxora™ and other pipeline candidates.
Investors following CALC news can expect regular updates on the Phase 2 KOURAGE trial of Auxora in patients with acute kidney injury (AKI) with associated respiratory failure, including disclosures about enrollment status, study design details, and anticipated data timing. CalciMedica also issues press releases on publications in peer-reviewed journals such as the American Journal of Nephrology and JCI Insight, which describe preclinical and translational data supporting CRAC channel inhibition in AKI and pulmonary arterial hypertension.
Another key news theme is the company’s acute pancreatitis (AP) program. CalciMedica reports on its discussions with the U.S. Food and Drug Administration regarding the design of a pivotal trial in AP and on collaborations, such as its agreement with Telperian, to apply artificial intelligence to completed Auxora trials and external datasets to refine trial design and patient selection. Conference participation and medical meeting symposia, including events focused on AKI, critical care nephrology, and pancreatitis, also feature prominently in the company’s announcements.
In addition, CalciMedica’s news releases cover quarterly financial results, cash runway commentary, equity offering updates, and corporate governance developments such as equity incentive plan amendments and board composition. For readers tracking CALC, this news page provides a consolidated view of operational milestones, scientific developments, and capital markets activity that shape the company’s clinical-stage trajectory in inflammatory and immunologic diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.